Skip to main content
RCUS
NYSE Life Sciences

Arcus Q3 Revenue Falls to $9M; $288M Raise Extends Cash Runway Into 2029

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Neutral
Importance info
7
Price
$19.31
Mkt Cap
$2.735B
52W Low
$17.43
52W High
$31.735
52W Position info
11% above low
Off High info
39% below high
Rel. Volume info
1.0× avg
Market data snapshot near publication time

RCUS is trading near its 52-week low of $17.43 (11% above the low).

Summary

Arcus reported Q3 revenue of $9 million versus $26 million a year ago and a $128 million net loss, but with $694 million in cash plus $288 million from its October raise it now has runway into 2029 while it advances casdatifan into first-line Phase 3.


Key Events · Earnings and Guidance · RCUS

  • Q3 Revenue Falls on Gilead Wind-Down

    Revenue was $9 million versus $26 million a year ago, driven by lower Gilead collaboration activity; full-year 2026 GAAP revenue is guided to $70-$75 million.

  • Cash Runway Extended Into 2029

    $694 million in cash and marketable securities at September 30 plus $288 million gross proceeds from the October equity financing funds planned operations into 2029.

  • Loss Narrows but Stays Large

    Net loss was $128 million ($1.00 per share) versus $135 million a year ago; R&D fell to $117 million from $141 million and G&A to $23 million from $27 million.

  • Casdatifan Phase 3 Milestones Ahead

    PEAK-1 second-line enrollment is expected complete in the next two to three months, and first-line PEAK-20 is on track to initiate by year-end 2026; more mature PFS/OS data expected in 2027.


Analysis · RCUS · Life Sciences

The balance sheet is the story here: $694 million in cash at quarter end plus $288 million gross from the October equity raise funds operations into 2029, removing near-term financing risk. That runway lets Arcus push casdatifan into first-line Phase 3 with PEAK-20 by year-end and complete PEAK-1 enrollment within two to three months. Revenue, meanwhile, dropped to $9 million from $26 million as Gilead collaboration work winds down, and the company still posted a $128 million quarterly net loss, leaving heavy reliance on casdatifan data in 2027.

How filings like this one have moved

In the 30 days to Nov 17, 2026, 38% of the 3791 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, RCUS was trading at $19.31 on NYSE in the Life Sciences sector, with a market capitalization of approximately $2.7B. The 52-week trading range was $17.43 to $31.74. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

RCUS - Latest Insights

RCUS
Nov 04, 2026, 4:05 PM EST
Source: BusinessWire
Importance Score:
7
Price at Filing: $19.31
Real-time Price: $15.76 info
Change: -$3.55 (-18%) info
Market Cap: $2.269B info
RCUS
Oct 21, 2026, 10:53 PM EDT
Source: BusinessWire
Importance Score:
7
Price at Filing: $18.03
Real-time Price: $15.76 info
Change: -$2.27 (-13%) info
Market Cap: $2.269B info
RCUS
Oct 21, 2026, 4:30 PM EDT
Filing Type: 424B5
Importance Score:
7
Price at Filing: $18.75
Real-time Price: $15.76 info
Change: -$2.99 (-16%) info
Market Cap: $2.269B info
RCUS
Oct 21, 2026, 4:22 PM EDT
Source: BusinessWire
Importance Score:
7
Price at Filing: $19.01
Real-time Price: $15.76 info
Change: -$3.25 (-17%) info
Market Cap: $2.269B info
RCUS
Oct 20, 2026, 12:16 PM EDT
Source: Seeking Alpha
Importance Score:
8
Price at Filing: $24.00
Real-time Price: $15.76 info
Change: -$8.24 (-34%) info
Market Cap: $2.269B info